Cytokines News and Research

Latest Cytokines News and Research

Recruitment complete in Oxagen's OC000459 IIb clinical trial for asthma

Oxagen Limited, a drug discovery and development company specializing in inflammation, today announced that the recruitment for its double blind, randomised, placebo controlled Phase IIb clinical trial in asthma with OC000459, its lead oral CRTH2 (DP2) antagonist, has now been completed.

9 Dec 2009

Research suggests that everyday germs may prevent diseases in adulthood

A new Northwestern University study suggests that American parents should ease up on antibacterial soap and perhaps allow their little ones a romp or two in the mud --- or at least a much better acquaintance with everyday germs.

9 Dec 2009

JAK2 inhibitor can control myelofibrosis, report researchers

A first-in-its class oral medication provides significant and durable relief for patients with a rare, debilitating and lethal bone marrow disorder called myelofibrosis, researchers at The University of Texas M. D. Anderson Cancer Center reported today at the 51st Annual Meeting of the American Society of Hematology.

8 Dec 2009

Prenatal exposure to microbes may help protect child from developing allergies later in life

A pregnant woman's exposure to microbes may protect her child from developing allergies later in life. Researchers in Marburg, Germany find that exposure to environmental bacteria triggers a mild inflammatory response in pregnant mice that renders their offspring resistant to allergies.

8 Dec 2009

CRO to run CEL-SCI's upcoming Phase III clinical trial

CEL-SCI Corporation, a late-stage oncology company and a developer of vaccines and therapeutics for the prevention and treatment of infectious diseases, announced today that it has retained the services of an international Contract Research Organization (CRO) to run CEL-SCI's upcoming Phase III clinical trial in advanced primary head and neck cancer with the Company's lead product candidate, Multikine®.

1 Dec 2009

Completion of Phase I study of CPSI-2364 announced by Cytokine PharmaSciences

Cytokine PharmaSciences, Inc. today announced the completion of a Phase I study of CPSI-2364, its orally active, small-molecule inhibitor of the production of TNF-alpha and other pro-inflammatory cytokines.

1 Dec 2009

University of Navarra Hospital launches clinical trials to assess the efficacy of immunotherapy treatment

The University of Navarra Hospital has launched a series of clinical trials in order to assess the efficacy of an immunotherapy treatment. This approach involves the application of personalised vaccines -produced from healthy and tumour cells from the patient him or herself- and designed to combat glioblastomas, one of the most aggressive and frequent malignant tumours.

1 Dec 2009

Clinical trials of personalised vaccines to fight glioblastomas

The University of Navarra Hospital has launched a series of clinical trials in order to assess the efficacy of an immunotherapy treatment. This approach involves the application of personalised vaccines —produced from healthy and tumour cells from the patient him or herself— and designed to combat glioblastomas, one of the most aggressive and frequent malignant tumours.

30 Nov 2009

Researchers identify a set of molecular brakes that stabilize the developing brain's circuitry

Researchers at the Stanford University School of Medicine have identified a set of molecular brakes that stabilize the developing brain's circuitry. Moreover, experimentally removing those brakes in mice enhanced the animals' performance in a test of visual learning, suggesting a long-term path to therapeutic application.

26 Nov 2009

Ohr Pharmaceutical to develop OHR/AVR118 for cachexia treatment

Ohr Pharmaceutical Inc. is developing OHR/AVR118 for treatment of cachexia based on technology acquired earlier this year from Advanced Viral Research Corp. OHR/AVR118 has shown excellent therapeutic efficacy and safety in human clinical trials in over 100 patients with applications for cachexia in Cancer and AIDS patients, as well as Rheumatoid Arthritis.

24 Nov 2009

Pediatric immunologist receives prestigious annual award from American Philosophical Society

A pediatric immunologist at The Children's Hospital of Philadelphia has received a prestigious annual award from the American Philosophical Society, an organization founded in 1743 by Benjamin Franklin. Jordan S. Orange, M.D., Ph.D., received the Society's Judson Daland Prize on Nov. 13 for his contributions to research and treatment of inherited immune deficiency diseases.

20 Nov 2009

GERD is an immune-mediated injury and not the result of acid burn, says new study

Contrary to current thinking, a condition called gastroesophageal reflux disease (GERD) might not develop as a direct result of acidic digestive juices burning the esophagus, UT Southwestern Medical Center researchers have found in an animal study.

20 Nov 2009

Altair Therapeutics initiates its IL-4 receptor alpha inhibitor bronchoprovocation phase 2 trial

Altair Therapeutics, Inc., a privately-held, biopharmaceutical company developing novel therapeutics for respiratory diseases, today announced the commencement of its IL-4 receptor alpha inhibitor bronchoprovocation trial. Study AIR645-CS2 is a phase 2, multi-center, randomized, double-blind, placebo-controlled study to assess the safety, tolerability, and efficacy of inhaled AIR645 in suppressing the asthmatic response in subjects with mild asthma. Results are expected in the third quarter of 2010.

19 Nov 2009

Embryonic stem cells raise hope of cellular replacement therapy for liver failure

Embryonic stem (ES) cells, known for their capacity to proliferate indefinitely and differentiate into almost all types of cells including hepatocytes, have raised the hope of cellular replacement therapy for liver failure. There have been several protocols available for hepatic fate specification from ES cells, however, most of the protocols currently used result in low yield or purity of functional hepatocytes. Valproic acid (VPA), a histone deacetylase inhibitor, has been demonstrated to facilitate the hepatic differentiation of mesenchymal stem cells. However, little is know about whether VPA could induce the hepatic differentiation of ES cells.

19 Nov 2009

Exaggerated responses of immune system explain elders’ susceptibility to viral infections

Researchers at Yale School of Medicine have found that exaggerated responses of the immune system explain why the elderly succumb to viral infections more readily than younger people. Published in the November 19 Cell Host & Microbe, the study bucks the general belief that declining immune responses are to blame for susceptibility to viral infections.

19 Nov 2009

Researchers discover new immune mechanism against viruses

Viruses are microscopically sized parasites. They plant their genes in the cells of their victim in order to 'reprogram' them. The infected cells then no longer produce what they need to live, making lots of new viruses instead.

16 Nov 2009

Research team identifies five new gene regions that raise the risk of childhood-onset IBD

In the largest, most comprehensive genetic analysis of childhood-onset inflammatory bowel disease (IBD), an international research team has identified five new gene regions, including one involved in a biological pathway that helps drive the painful inflammation of the digestive tract that characterizes the disease.

16 Nov 2009

ImmunoLin provides immediate benefit to the function of immune system and gut

A new study provides evidence that ImmunoLin®, an all natural and GRAS approved source of immunoglobulin, will provide immediate benefit to the function of the immune system and the gut. Immunoglobulins, or antibodies, are specialized proteins found in blood that the immune system naturally produces for immunity.

6 Nov 2009

Idera Pharmaceuticals announces financial results for the third quarter of 2009

Idera Pharmaceuticals, Inc. today reported financial results for the third quarter and nine months ended September 30, 2009.

5 Nov 2009

Smokers with systemic lupus erythematosus at greater risk of skin damage and rashes

As if there weren't enough reasons to stop smoking, a team of researchers at the Research Institute of the McGill University Health Centre (RI-MUHC) have just found another. A study led by Dr. Christian A Pineau, Co-Director of the Lupus and Vasculitis clinic at the MUHC, has clearly linked skin damage and rashes to smoking in people with systemic lupus erythematosus (SLE). The study was published in a recent issue of the Journal of Rheumatology.

3 Nov 2009

Cytokines News and Research

Latest Cytokines News and Research

Recruitment complete in Oxagen's OC000459 IIb clinical trial for asthma

Research suggests that everyday germs may prevent diseases in adulthood

JAK2 inhibitor can control myelofibrosis, report researchers

Prenatal exposure to microbes may help protect child from developing allergies later in life

CRO to run CEL-SCI's upcoming Phase III clinical trial

Completion of Phase I study of CPSI-2364 announced by Cytokine PharmaSciences

University of Navarra Hospital launches clinical trials to assess the efficacy of immunotherapy treatment

Clinical trials of personalised vaccines to fight glioblastomas

Researchers identify a set of molecular brakes that stabilize the developing brain's circuitry

Ohr Pharmaceutical to develop OHR/AVR118 for cachexia treatment

Pediatric immunologist receives prestigious annual award from American Philosophical Society

GERD is an immune-mediated injury and not the result of acid burn, says new study

Altair Therapeutics initiates its IL-4 receptor alpha inhibitor bronchoprovocation phase 2 trial

Embryonic stem cells raise hope of cellular replacement therapy for liver failure

Exaggerated responses of immune system explain elders’ susceptibility to viral infections

Researchers discover new immune mechanism against viruses

Research team identifies five new gene regions that raise the risk of childhood-onset IBD

ImmunoLin provides immediate benefit to the function of immune system and gut

Idera Pharmaceuticals announces financial results for the third quarter of 2009

Smokers with systemic lupus erythematosus at greater risk of skin damage and rashes

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Cytokines News and Research

Latest Cytokines News and Research

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Newsletters you may be interested in